Stopping Somatostatin Analogues After PRRT for NETs
Part of Cancer clinical trials.
This trial tests whether it's safe to stop somatostatin analogues (SSAs) after PRRT (a type of radiation therapy for neuroendocrine tumors). It is for people with midgut, hindgut, or pancreatic NETs that have not responded to SSAs and now need PRRT.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a midgut, hindgut, or pancreatic NET that is well or moderately differentiated (WHO grade 1 or 2).
- Your tumor must be growing despite treatment with somatostatin analogues (like Sandostatin or Somatuline) at standard doses for at least 12 weeks.
- Your doctor has recommended PRRT as the next best treatment, and you have not had PRRT before.
- You are willing to either stop or continue your somatostatin analogue treatment based on the study arm you are assigned to.
- Your NET is non-functioning (not causing flushing or diarrhea from hormones), and you have not needed extra doses of somatostatin for symptoms.
- You have good enough organ function and an expected survival of at least 12 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining peptide receptor radionuclide therapy (PRRT) with long-acting somatostatin analogues to see how much radiation reaches the tumor. It is for people with neuroendocrine tumors who meet the standard criteria for PRRT.
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
This Phase 1 study tests how safe and effective it is to combine a PARP inhibitor (a targeted cancer medicine) with PRRT, a treatment that delivers radiation directly to certain tumor cells. It is for people with grade 2 neuroendocrine tumors from the pancreas or intestines, especially when scans suggest the tumor will take up the targeted radiation.
This Phase 3 trial tests RYZ101 versus standard of care in people with inoperable, well-differentiated SSTR-positive GI or pancreas neuroendocrine tumors (NETs) that keep growing after Lu-177 SSA. It may help by improving tumor control after your prior targeted radiation treatment.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.